A phase II study of sorafenib in patients with metastatic renal cell carcinoma
Phase of Trial: Phase II
Latest Information Update: 24 May 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Adverse reactions
- 10 May 2016 Status changed from active, no longer recruiting to discontinued due to low accrual rate.
- 07 Aug 2012 Company added in association field as reported by ClinicalTrials.gov.
- 01 Nov 2010 Planned End Date changed from 1 Jan 2009 to 1 Jan 2015 as reported by ClinicalTrials.gov.